AGN, LLY, BIIB, CELG And AMGN, Pushing Health Care Sector Downward

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Two out of the three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 1 points (0.0%) at 15,277 as of Thursday, May 16, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 1,398 issues advancing vs. 1,509 declining with 138 unchanged.

The Health Care sector currently sits down 0.72 versus the S&P 500, which is down 0.10. On the negative front, top decliners within the sector include Biomarin Pharmaceutical ( BMRN), down 6.00, Alexion Pharmaceuticals ( ALXN), down 4.57, Bristol-Myers Squibb Company ( BMY), down 3.51, Vertex Pharmaceuticals ( VRTX), down 3.07 and Gilead ( GILD), down 3.16. A company within the sector that increased today was UnitedHealth Group ( UNH), up 0.54.

TheStreet Ratings group would like to highlight 5 stocks pushing the sector lower today:

5. Allergan ( AGN) is one of the companies pushing the Health Care sector lower today. As of noon trading, Allergan is down $1.78 (-1.7%) to $101.04 on average volume Thus far, 1.2 million shares of Allergan exchanged hands as compared to its average daily volume of 1.7 million shares. The stock has ranged in price between $100.09-$102.50 after having opened the day at $102.50 as compared to the previous trading day's close of $102.82.

Allergan, Inc. operates as a multi-specialty healthcare company primarily in the United States, Europe, Latin America, and the Asia Pacific. Allergan has a market cap of $30.8 billion and is part of the drugs industry. The company has a P/E ratio of 27.8, above the S&P 500 P/E ratio of 17.7. Shares are up 12.1% year to date as of the close of trading on Wednesday.

TheStreet Ratings rates Allergan as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, impressive record of earnings per share growth, notable return on equity, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Allergan Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

4. As of noon trading, Eli Lilly and Company ( LLY) is down $0.56 (-1.0%) to $56.16 on light volume Thus far, 1.8 million shares of Eli Lilly and Company exchanged hands as compared to its average daily volume of 5.2 million shares. The stock has ranged in price between $55.86-$56.56 after having opened the day at $56.56 as compared to the previous trading day's close of $56.72.

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. Eli Lilly and Company has a market cap of $62.9 billion and is part of the drugs industry. The company has a P/E ratio of 13.4, below the S&P 500 P/E ratio of 17.7. Shares are up 15.0% year to date as of the close of trading on Wednesday.

TheStreet Ratings rates Eli Lilly and Company as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, increase in net income, notable return on equity, reasonable valuation levels and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Eli Lilly and Company Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

3. As of noon trading, Biogen Idec ( BIIB) is down $1.67 (-0.7%) to $225.46 on average volume Thus far, 648,630 shares of Biogen Idec exchanged hands as compared to its average daily volume of 1.4 million shares. The stock has ranged in price between $223.11-$227.64 after having opened the day at $226.68 as compared to the previous trading day's close of $227.13.

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Biogen Idec has a market cap of $54.6 billion and is part of the drugs industry. The company has a P/E ratio of 36.5, above the S&P 500 P/E ratio of 17.7. Shares are up 57.0% year to date as of the close of trading on Wednesday.

TheStreet Ratings rates Biogen Idec as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, compelling growth in net income and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Biogen Idec Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

2. As of noon trading, Celgene Corporation ( CELG) is down $6.20 (-4.8%) to $123.43 on heavy volume Thus far, 2.9 million shares of Celgene Corporation exchanged hands as compared to its average daily volume of 3.3 million shares. The stock has ranged in price between $122.61-$128.83 after having opened the day at $128.29 as compared to the previous trading day's close of $129.63.

Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies to treat cancer and immune-inflammatory related diseases in the United States, Europe, and other countries. Celgene Corporation has a market cap of $54.3 billion and is part of the drugs industry. The company has a P/E ratio of 39.6, above the S&P 500 P/E ratio of 17.7. Shares are up 65.9% year to date as of the close of trading on Wednesday.

TheStreet Ratings rates Celgene Corporation as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, good cash flow from operations, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Celgene Corporation Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

1. As of noon trading, Amgen ( AMGN) is down $2.34 (-2.2%) to $105.08 on average volume Thus far, 2.0 million shares of Amgen exchanged hands as compared to its average daily volume of 4.4 million shares. The stock has ranged in price between $103.60-$107.03 after having opened the day at $107.03 as compared to the previous trading day's close of $107.42.

Amgen Inc., a biotechnology medicines company, engages in the discovery, development, manufacture, and marketing of human therapeutic products in the areas of supportive cancer care, inflammation, nephrology, and bone diseases primarily in the United States, Europe, and Canada. Amgen has a market cap of $81.0 billion and is part of the drugs industry. The company has a P/E ratio of 18.2, above the S&P 500 P/E ratio of 17.7. Shares are up 25.2% year to date as of the close of trading on Wednesday.

TheStreet Ratings rates Amgen as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, revenue growth and notable return on equity. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Amgen Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

If you are interested in one of these 4 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

A reminder about TheStreet Ratings group: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.
null